Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: J Mol Cell Cardiol. 2018 May 9;119:147–154. doi: 10.1016/j.yjmcc.2018.05.007

Figure 1.

Figure 1

R9C hiPSC-CMs demonstrate a blunted response to β-agonist and adenylate cyclase activators. (A) Representative calcium transients of R9C hiPSC-CMs at day 35 of differentiation (stimulated at 40V, paced at 0.5Hz) compared to isogenic wild-type controls under basal conditions (top) and following treatment with 500nM isoproterenol or forskolin (bottom). (B) Quantification of calcium amplitude and time for relaxation (tau) were performed for wild-type and both inserted R9C clones in hiPSC-CMs at day 35. White bar = basal conditions; red bar = 500nM isoproterenol; blue bar = 500nM forskolin (N=10–12).